A practical guide to what claims data captures, how India compares to US and EU sources, and how Medical Affairs teams turn billing records into market access evidence.
Executive Summary (TL;DR)
The Underused Asset: Claims data captures how patients are actually treated in the real world. Trial data can't tell you what doctors choose when they have options, how long patients stay on therapy, or what the total cost of care looks like. Claims data can.
The Strategy: It's never one-size-fits-all. Private insurer data reflects working-age, employed populations. PMJAY data gets you into government-scheme beneficiaries. Hospital billing data fills the inpatient and procedural gaps. The right answer comes from matching your question to the right source, not from defaulting to whatever's easiest to access.
The Imperative: Payers across the world are asking harder questions at submission. They want comparative effectiveness against real alternatives, real-world adherence numbers, and a credible cost-of-care story. Brands that build this evidence early walk into those conversations prepared.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. Claims data analytics turns routine billing records into structured evidence on treatment patterns
A pharma brand needs to know how its therapy compares against the active competitor in routine clinical practice. A clinical trial cannot answer the question — the trial compared against placebo, and the timeline to commission a head-to-head Phase 4 study runs into years. Claims data analytics answers it in weeks. The brand can identify all patients in a major insurer’s database who started either therapy in the past three years, follow their hospitalisation rates, treatment switches, and adherence patterns, and produce comparative effectiveness evidence the payer committee will accept.
This is the underused power of claims data analytics in pharma. Insurance billing records and hospital claims were never designed for pharmaceutical evidence generation, but the data they capture — every diagnosis code, procedure, prescription fill, and hospitalisation across the insured population — answers questions that pivotal trials structurally cannot. Brands that build claims data capability turn this routine administrative byproduct into one of the highest-impact evidence assets in their portfolio.
Claims data captures the financial transactions of healthcare delivery — every billable encounter, procedure, prescription, and hospitalisation that an insurer or government scheme reimburses. Each transaction generates a structured record with the patient identifier (de-identified for research), provider, diagnosis codes, procedure codes, prescription details, and dates of service.
The analytic value emerges from aggregation. Claims data analytics in pharma typically supports four data types: diagnosis patterns showing the prevalence and incidence of conditions across the insured population, treatment patterns showing which therapies patients receive in which sequences and switching behaviour, healthcare resource utilisation including hospitalisations, emergency department visits, and outpatient encounters, and pharmacy data including initial prescription, persistence, refill behaviour, and discontinuation.
What claims data does not capture is equally important. Clinical severity, lab values, patient-reported outcomes, and qualitative aspects of care fall outside the billing system. A diabetes claims record shows the patient was prescribed a specific drug but does not show their HbA1c trajectory; a heart failure claim shows hospitalisation but does not show ejection fraction. Sponsors expecting claims data to substitute for clinical trial endpoints will be disappointed; sponsors using claims data to answer the questions clinical trials cannot answer will not.
“A typical pharmaceutical claims database analysis can characterise treatment patterns and comparative effectiveness across 50,000 to 5 million patients in three to six months — generating evidence that would require five to seven years and a large multi-site Phase 4 trial to produce.”
Claims data ecosystems vary significantly across major pharma markets, with implications for evidence generation strategy.
The United States offers the most mature commercial claims data ecosystem. Major datasets — Optum, IBM MarketScan (now Merative), Inovalon, IQVIA Real-World Data — aggregate claims across multiple insurers and self-insured employers, covering tens of millions of patients with multi-year longitudinal follow-up. Medicare and Medicaid datasets add public payer coverage. Linked datasets connecting claims to lab values, EMR data, and mortality records provide the most analytically powerful environment globally.
European claims environments are more variable. National health system data — UK Clinical Practice Research Datalink, French SNDS, Danish national registers, Swedish prescribed drug register — provide population-scale coverage in countries with single-payer systems. Germany’s statutory health insurance data and Italy’s regional databases offer comparable depth. The trade-off is access complexity: each national system has distinct governance, ethics, and analytic frameworks that sponsors must navigate.
Indian claims data sits at an earlier maturity stage but is moving rapidly. Private health insurer data through major TPAs covers India’s middle and upper-middle-class population. PMJAY claims cover government-scheme beneficiaries at scale. CGHS, ECHS, and state scheme datasets capture employee and pensioner populations. The remaining gap is integrated multi-payer aggregation — no Indian equivalent of MarketScan exists yet — but several Indian health analytics firms now build aggregated, de-identified Indian claims environments suitable for pharmaceutical research.
Five evidence questions consistently justify claims data analytics investment in pharma.
Comparative effectiveness against active comparators is the highest-value use case. Where pivotal trials compared against placebo, claims data identifies real-world cohorts of patients on each comparator and compares hospitalisation rates, treatment switches, healthcare resource utilisation, and total cost of care. Modern propensity score methods address baseline confounding, producing payer-grade comparative evidence at a fraction of the cost of head-to-head trials.
Treatment pattern characterisation supports launch positioning and HCP targeting. Claims data shows which therapies are used in which patient profiles, which sequences are common, where treatment failures occur, and which physician segments drive prescribing. This intelligence shapes sales force deployment, KOL engagement, and patient support programme design.
Adherence and persistence analysis directly populates HEOR cost-effectiveness models. A drug with strong trial efficacy but poor real-world persistence delivers different outcomes than its trial data suggested. Claims-based persistence analysis quantifies the gap and informs the value calculation payers actually use.
Burden-of-illness and cost-of-care studies establish the economic baseline against which a new therapy is evaluated. Hospitalisation rates, outpatient utilisation, productivity loss proxies, and total annual cost figures from claims data feed directly into payer dossiers and HTA submissions.
Disease epidemiology and unmet need quantification supports pre-launch positioning. How many patients in the target indication exist in the addressable insured population? What is their current treatment journey? What share of patients fail current therapy and remain candidates for a new option? Claims data answers each question with population-level evidence rather than market research extrapolation.
→ Match your market access question to the right claims data source — and the right analytic method. → Engage OneAlphaMed Medical Affairs
Claims data analytics in pharma fails most often at the methodological layer, not the data access layer. Five pitfalls recur across studies.
Confounding by indication is the structural challenge. Patients prescribed therapy A differ systematically from patients prescribed therapy B in ways that affect outcomes independent of the treatments. Modern propensity score matching, inverse probability weighting, and instrumental variable methods address this, but only when applied with methodological care. Naive comparisons of treated cohorts produce biased estimates that sophisticated payer reviewers immediately discount.
New-user versus prevalent-user bias compromises retrospective designs. Including patients already on therapy at baseline produces a survival-biased cohort — the patients tolerating the therapy long enough to appear in the dataset. New-user designs, restricting analysis to patients newly initiating therapy, produce more interpretable results.
Outcome misclassification follows from claims-based outcome definitions. A “hospitalisation for heart failure” defined by primary diagnosis code captures a different cohort than one defined by any-listed diagnosis code or by procedure-code triangulation. Operational definitions must be pre-specified and validated where possible.
Loss to follow-up and disenrollment produce informative censoring. Patients leaving the dataset — through plan changes, employment changes, or coverage gaps — may differ systematically from those who remain. Sensitivity analyses must address this directly.
Regression to the mean affects pre-post studies of healthcare utilisation. A patient hospitalised in the past year is more likely to have lower utilisation in the following year regardless of treatment. Comparison-group designs and appropriate statistical controls address this; single-arm pre-post studies typically do not.
Pharma teams that consistently extract value from claims data analytics share three operational characteristics.
They invest in dedicated analytic infrastructure. This means partnerships with specialised claims data vendors, in-house epidemiologists or HEOR analysts who understand the dataset structure, and statistical computing capability sufficient for propensity score matching, sensitivity analyses, and survival modelling.
They engage early in the asset lifecycle. Claims data evidence is most valuable when generated before launch — establishing comparator outcomes, characterising the treatment landscape, identifying target patient profiles. Brands waiting until post-launch reproduce the comparator’s narrative rather than shaping their own.
They integrate claims data analytics with broader RWE strategy. Claims data alone answers some questions; combined with hospital EMR partnerships, registry data, or patient-reported outcomes, it answers many more. The brands that win formulary battles deploy claims data as one component of an integrated evidence portfolio, not as a standalone tactic.
For Indian markets, this discipline extends to local capability. Indian claims coding, payer dynamics, and regulatory expectations differ from Western environments. Sponsors building India-specific claims capability — through TPA partnerships, PMJAY research access, and India-resident health analytics expertise — generate evidence that local payers find credible.
Claims data analytics has moved from a niche HEOR tactic to a core evidence discipline in pharmaceutical Medical Affairs. The brands that treat claims data as routine evidence infrastructure — alongside clinical trials, registries, and hospital partnerships — generate comparative effectiveness, treatment-pattern, and adherence evidence that shapes formulary outcomes. The brands that treat claims data as an occasional study type produce occasional studies whose impact decays before the next payer committee meets.
The competitive question is no longer whether to invest in claims data capability. It is whether the capability is built and operating before the next major launch, label extension, or payer renegotiation. Brands building it now will compete with evidence depth that brands deferring it cannot match.
OneAlphaMed helps Medical Affairs and Market Access teams design claims data analytics that generate payer-grade comparative effectiveness evidence. Explore our Medical Affairs practice →
Claims data analytics characterises diagnosis patterns, treatment sequences, comparator effectiveness, healthcare resource utilisation, hospitalisations, and prescription persistence across insured populations. It generates population-level evidence on real-world treatment behaviour and outcomes that clinical trials structurally cannot produce, supporting market access submissions, HTA dossiers, and brand positioning.
The US offers the most mature commercial claims environment with multi-payer aggregated datasets covering tens of millions of patients. Europe relies on national health system datasets in single-payer countries. Indian claims data sits at an earlier maturity stage, with private insurer data through TPAs, PMJAY for government-scheme beneficiaries, and increasingly available aggregated environments through India-specific health analytics firms.
Claims data is ideal when there is a requirement for quick and cost-effective real-world evidence.It's specifically beneficial to compare how your drug performs against actual alternatives patients are already taking, not just placebo. You can also map out how patients are currently being treated - who gets what, in what sequence which directly informs positioning and targeting strategies. For payer submissions, claims data helps build burden-of-illness stories and estimate cost-of-care, while adherence and persistence patterns feed into your HEOR models. Pre-launch, it helps size the patient population and understand disease epidemiology before you've sold a single unit.
The biggest one is confounding by indication - sicker patients often get different treatments, so naïve comparisons mislead. Choosing patients mid-treatment (prevalent-user bias) results in skewed findings. You can end up having miscoded or missed outcomes, and patients dropping out of insurance plans creates informative censoring that distorts survival analyses. Pre-post designs often catch patients at their worst, so improvement looks bigger than it really is. The fixes exist - new-user designs, propensity scoring, validated outcome definitions but only if your team knows to apply them from the start.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
